[go: up one dir, main page]

WO1994018316A3 - Apolipoprotein b mrna editing protein compositions and methods - Google Patents

Apolipoprotein b mrna editing protein compositions and methods Download PDF

Info

Publication number
WO1994018316A3
WO1994018316A3 PCT/US1994/001422 US9401422W WO9418316A3 WO 1994018316 A3 WO1994018316 A3 WO 1994018316A3 US 9401422 W US9401422 W US 9401422W WO 9418316 A3 WO9418316 A3 WO 9418316A3
Authority
WO
WIPO (PCT)
Prior art keywords
apo
apolipoprotein
methods
editing protein
protein compositions
Prior art date
Application number
PCT/US1994/001422
Other languages
French (fr)
Other versions
WO1994018316A2 (en
Inventor
Babie Teng
Nicholas Davidson
Charles F Burant
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/015,203 external-priority patent/US5550034A/en
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Priority to AU61360/94A priority Critical patent/AU6136094A/en
Priority to EP94908009A priority patent/EP0682701A1/en
Publication of WO1994018316A2 publication Critical patent/WO1994018316A2/en
Publication of WO1994018316A3 publication Critical patent/WO1994018316A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a protein that edits apo B RNA. A polynucleotide that comprises a DNA sequence that encodes an apo B RNA editing protein and an expression vector comprising such a polynucleotide are also provided. Processes for producing an apo B RNA editing protein, editing apo B RNA and altering apo B protein production are also provided.
PCT/US1994/001422 1993-02-09 1994-02-08 APOLIPOPROTEIN B mRNA EDITING PROTEIN COMPOSITIONS AND METHODS WO1994018316A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU61360/94A AU6136094A (en) 1993-02-09 1994-02-08 Apolipoprotein b mrna editing protein compositions and methods
EP94908009A EP0682701A1 (en) 1993-02-09 1994-02-08 APOLIPOPROTEIN B mRNA EDITING PROTEIN COMPOSITIONS AND METHODS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/015,203 1993-02-09
US08/015,203 US5550034A (en) 1992-12-04 1993-02-09 Apolipoprotein B mRNA editing protein compositions and methods
US08/158,682 US5434058A (en) 1993-02-09 1993-11-24 Apolipoprotein B MRNA editing protein compositions and methods
US08/158,682 1993-11-24

Publications (2)

Publication Number Publication Date
WO1994018316A2 WO1994018316A2 (en) 1994-08-18
WO1994018316A3 true WO1994018316A3 (en) 1994-09-29

Family

ID=26687076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/001422 WO1994018316A2 (en) 1993-02-09 1994-02-08 APOLIPOPROTEIN B mRNA EDITING PROTEIN COMPOSITIONS AND METHODS

Country Status (4)

Country Link
US (1) US5434058A (en)
EP (1) EP0682701A1 (en)
AU (1) AU6136094A (en)
WO (1) WO1994018316A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010322A1 (en) * 1992-10-29 1994-05-11 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
US5702948A (en) * 1995-02-02 1997-12-30 The Trustees Of The University Of Pennsylvania Saccular collagen and compositions and methods for making and using the same
IT1275909B1 (en) * 1995-03-07 1997-10-24 Mirella Pilone FRAGMENT OF DNA CODING D-AMINO ACID OXIDASE
US5866333A (en) * 1996-03-01 1999-02-02 Regents Of The University Of California Screening methods to detect mRNA targets of editing enzymes
US5747319A (en) * 1996-07-25 1998-05-05 Incyte Pharmaceuticals, Inc. Human mRNA editing enzyme
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
US5804185A (en) * 1997-03-13 1998-09-08 Incyte Pharmaceuticals, Inc. RNA editing enzyme REE-2
FR2762014B1 (en) * 1997-04-10 1999-06-04 Itzik Harosh USE OF APOBEG1 OR RELATED PROTEINS OR GENES CAUSING ANDERSONS DISEASE AS A TARGET FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY AND RELATED TECHNIQUES FOR CLONING AND SCREENING FOR INHIBITORS
PT1049767E (en) 1998-01-08 2005-10-31 Agronomique Inst Nat Rech TRANSGENIC RABBIT EXPRESSING A HUMAN FUNCTIONAL LIPOPROTEIN (A)
DE10102977A1 (en) * 2001-01-23 2002-08-01 Thomas Jentsch Test system for the development of therapeutic agents, in particular active ingredients for the treatment of osteoporosis
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7888324B2 (en) * 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2003022228A2 (en) * 2001-09-13 2003-03-20 California Institute Of Technology Method for producing transgenic birds and fish
US7169548B2 (en) * 2002-09-13 2007-01-30 Xy, Inc. Sperm cell processing and preservation systems
US7511131B2 (en) * 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
WO2006020676A2 (en) * 2004-08-10 2006-02-23 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
JP2010522245A (en) * 2007-03-24 2010-07-01 ゲンザイム コーポレイション Administration of antisense oligonucleotide complementary to human apolipoprotein B
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
EP2655614B1 (en) 2010-12-22 2017-03-15 President and Fellows of Harvard College Continuous directed evolution
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2014018195A1 (en) * 2012-06-21 2014-01-30 Monsanto Technology Llc Lysis buffer and methods for extraction of dna from plant material
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
CN108513575A (en) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 Nucleobase editors and their uses
CN110214183A (en) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 Adenosine nucleobase editing machine and application thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (en) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 AAV delivery of nucleobase editor
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (en) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
JP2020534795A (en) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and Compositions for Evolving Base Editing Factors Using Phage-Supported Continuous Evolution (PACE)
WO2019040935A1 (en) 2017-08-25 2019-02-28 President And Fellows Of Harvard College Evolution of bont peptidases
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019241649A1 (en) * 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
DE112021002672T5 (en) 2020-05-08 2023-04-13 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BABIE TENG ET AL.: "Molecular cloning of an apolipoprotein B messenger RNA editing protein", SCIENCE, vol. 260, June 1993 (1993-06-01), LANCASTER, PA US, pages 1816 - 1819 *
CHAN, L.: "RNA editing: exploring one mode with apolipoprotein B mRNA", BIOESSAYS, vol. 15, no. 1, January 1993 (1993-01-01), pages 33 - 41 *
DRISCOLL D. M. ET AL.: "An in vitro system for the editing of apolipoprotein B mRNA", CELL, vol. 58, 1989, CAMBRIDGE, NA US, pages 519 - 525 *
GREEVE J. ET AL.: "Characterization of the apolipoprotein B mRNA editing enzyme: no similarity to the proposed mechanism of RNA editing in kinetoplastid protozoa", NUCLEIC ACIDS RESEARCH, vol. 19, no. 13, 1991, ARLINGTON, VIRGINIA US, pages 3569 - 3576 *
HODGES P. E. ET AL.: "Site-specific creation of uridine from cytidine in apolipoprotein B mRNA editing", NUCLEIC ACIDS RESEARCH, vol. 19, no. 6, 1991, ARLINGTON, VIRGINIA US, pages 1197 - 1201 *
NAVEENAN NAVARATNAM ET AL.: "Apolipoprotein B mRNA editing is associated with UV crosslinking of proteins to the editing site", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, January 1993 (1993-01-01), WASHINGTON US, pages 222 - 226 *
NAVEENAN NAVARATNAM ET AL.: "The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 268, no. 28, October 1993 (1993-10-01), BALTIMORE, MD US, pages 20709 - 20712 *

Also Published As

Publication number Publication date
EP0682701A1 (en) 1995-11-22
AU6136094A (en) 1994-08-29
US5434058A (en) 1995-07-18
WO1994018316A2 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
WO1994018316A3 (en) Apolipoprotein b mrna editing protein compositions and methods
EP0656954A4 (en) Method for producing tagged genes, transcripts, and proteins.
EP0832975A3 (en) Histidinol dehydrogenase from Staphylococcus aureus
DE3585953D1 (en) DNA FRAGMENTS, EXPRESSION VECTORS, PROTEINS, INNOVATORS AND METHOD FOR PRODUCING THE PROTEINS.
WO1999020799A3 (en) Microorganism genomics, compositions and methods related thereto
WO2000018914A3 (en) Novel dkr polypeptides
WO1998021333A3 (en) Nucleic acid encoding schwannomin-binding-proteins and products related thereto
EP0869174A3 (en) Method for cloning and producing the SpeI restriction endonuclease
DE3686969D1 (en) CURABLE COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND ITEMS PRODUCED FROM IT.
EP0620284A3 (en) Process for producing patented steel wire.
AU1322692A (en) Method for the in vitro production of protein from a dna sequence without cloning
WO1995006733A3 (en) Glycerin-3-phosphate-dehydrogenase (gpdh)
EP0832978A3 (en) Novel 3-dehydroquinate synthase
AU1720397A (en) Recombinant expression of s-layer proteins
EP0607005A3 (en) Isolated DNA encoding the Not I restriction endonuclease and related methods for producing the same.
WO1997029194A3 (en) Preparation of l-ascorbic acid
CA2194032A1 (en) Fused dna sequence, fused protein expressed from said fused dna sequence and method for expressing said fused protein
AU6126396A (en) Method for identifying secretory genes from helicobacter pylori
DE69811677D1 (en) METHOD FOR THE PREPARATION OF ENANTIOMER-ENRICHED, N-DERIVATIVED LACTAMES.
EP0931835A3 (en) Method for cloning and producing the PmeI restriction endonuclease
EP0620439A3 (en) Method of determining the binding of transcription factors to nucleic acids.
DE69022165D1 (en) Cloning plasmid vector, primer vector thereof and cDNA library production method.
CA2243578A1 (en) High affinity nucleic acid ligands of complement system proteins
EP0843014A3 (en) Tryptophanyl tRNA synthetase
WO2002024904A3 (en) Method for producing ribonucleic acid (rna)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994908009

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994908009

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994908009

Country of ref document: EP